ArticleArquivos brasileiros de cardiologia2026
Astragalus Polysaccharide Enhances Mitochondrial Biogenesis and Function in Cardiomyocytes Through AMPK Activation.
Article in Arquivos brasileiros de cardiologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMitochondrial dysfunction is a key driver of heart failure, underscoring the need for therapies that promote mitochondrial biogenesis and function. Astragalus polysaccharide (APS), a bioactive compound from Astragalus membranaceus, has demonstrated cardioprotective properties, but its direct effects on mitochondrial homeostasis in cardiomyocytes remain unclear.
objectivesThis study aimed to investigate the effects of APS on mitochondrial function and biogenesis in HL-1 cardiomyocytes and to elucidate the involvement of the AMP-activated protein kinase (AMPK)/peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) signaling pathway.
methodsHL-1 cardiomyocytes were treated with non-toxic concentrations of APS (1.25-2.5 g/L) for 48 hours. Mitochondrial respiration was assessed via Seahorse XF Analyzer, adenosine triphosphate (ATP) levels were quantified, and Complex IV activity was measured. Mitochondrial biogenesis was evaluated by mitochondrial DNA (mtDNA)/ nuclear DNA (nDNA) ratio, cytochrome B levels, and mitochondrial mass. Key proteins and genes, including PGC-1α, nuclear respiratory factor 2 (NRF2), mitochondrial transcription factor A (TFAM), uncoupling protein 2 (UCP2), and phosphorylated AMPK (p-AMPK), were analyzed by Western blot and qPCR. The AMPK inhibitor Compound C was used to confirm the pathway's role.
resultsAPS treatment significantly enhanced mitochondrial respiration, ATP production, and Complex IV activity. It promoted mitochondrial biogenesis, evidenced by increased mtDNA/nDNA ratio and mitochondrial mass. APS upregulated the expression of PGC-1α, NRF2, TFAM, and UCP2, and activated AMPK phosphorylation. All these beneficial effects were abolished by AMPK inhibition with Compound C.
conclusionsAPS enhances mitochondrial biogenesis and function in cardiomyocytes through activation of the AMPK/PGC-1α signaling pathway, identifying it as a potential therapeutic agent for cardiac diseases associated with mitochondrial dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.